Pada bulan Desember 2020, ''Committee for Medicinal Products for Human Use'' (CHMP) dari [[Badan Pengawas Obat-obatan Eropa]] mengadopsi opini positif, merekomendasikan pemberian otorisasi pemasaran untuk produk obat Kixelle, yang ditujukan untuk pengobatan diabetes.<ref>{{cite web | title=Kixelle: Pending EC decision | website=[[European Medicines Agency]] (EMA) | date=10 December 2020 | url=https://www.ema.europa.eu/en/medicines/human/summaries-opinion/kixelle | access-date=12 December 2020 | archive-date=12 December 2020 | archive-url=https://web.archive.org/web/20201212165133/https://www.ema.europa.eu/en/medicines/human/summaries-opinion/kixelle | url-status=live }}</ref> Pemohon untuk produk obat ini adalah Mylan IRE Healthcare Limited. Kixelle disetujui untuk penggunaan medis di Uni Eropa pada bulan Februari 2021.<ref>{{cite web | title=Kixelle EPAR | website=[[European Medicines Agency]] (EMA) | date=9 December 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/kixelle | access-date=16 March 2021 | archive-date=29 June 2021 | archive-url=https://web.archive.org/web/20210629235515/https://www.ema.europa.eu/en/medicines/human/EPAR/kixelle | url-status=live }}</ref> Kixelle berganti nama menjadi Kirsty.<ref name="Kirsty EPAR">{{cite web | title=Kirsty EPAR | website=[[European Medicines Agency]] (EMA) | date=9 December 2020 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/kirsty-previously-kixelle | access-date=14 September 2021 | archive-date=15 September 2021 | archive-url=https://web.archive.org/web/20210915064025/https://www.ema.europa.eu/en/medicines/human/EPAR/kirsty-previously-kixelle | url-status=live }}</ref>
Trurapi disetujui untuk penggunaan medis di Kanada pada bulan Oktober 2020.<ref>{{cite web | title=Summary Basis of Decision (SBD) for Trurapi | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00515&lang=en | access-date=29 May 2022 | archive-date=30 May 2022 | archive-url=https://web.archive.org/web/20220530050752/https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00515&lang=en | url-status=live }}</ref>
